Clinical Trial Update: PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy [Phase 1]

View source ↗

Summary

A Phase 1 study of a PI3K delta inhibitor in relapsed or refractory autoimmune hemolytic anemia after two or more lines of therapy has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Hemolytic Anemia

Drugs mentioned

• PI3K delta inhibitor (unnamed) (PI3K delta inhibitor)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Autoimmune Hemolytic Anemia, Failure of Two Rounds of Treatment | Phase 1 | Status: TERMINATED